DK0813541T3 - Fremgangsmåde til fremstilling af et protein - Google Patents
Fremgangsmåde til fremstilling af et proteinInfo
- Publication number
- DK0813541T3 DK0813541T3 DK96906136T DK96906136T DK0813541T3 DK 0813541 T3 DK0813541 T3 DK 0813541T3 DK 96906136 T DK96906136 T DK 96906136T DK 96906136 T DK96906136 T DK 96906136T DK 0813541 T3 DK0813541 T3 DK 0813541T3
- Authority
- DK
- Denmark
- Prior art keywords
- apoe
- apoa
- matrix
- endotoxins
- aqueous solution
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9500778A SE9500778D0 (sv) | 1995-03-03 | 1995-03-03 | Process for producing a protein |
PCT/SE1996/000271 WO1996027608A1 (en) | 1995-03-03 | 1996-03-01 | Process for producing a protein |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0813541T3 true DK0813541T3 (da) | 2003-09-15 |
Family
ID=20397430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK96906136T DK0813541T3 (da) | 1995-03-03 | 1996-03-01 | Fremgangsmåde til fremstilling af et protein |
Country Status (15)
Country | Link |
---|---|
US (3) | US5834596A (da) |
EP (1) | EP0813541B1 (da) |
JP (1) | JPH11501046A (da) |
AT (1) | ATE240348T1 (da) |
AU (1) | AU694623B2 (da) |
CA (1) | CA2212125A1 (da) |
DE (1) | DE69628148T2 (da) |
DK (1) | DK0813541T3 (da) |
ES (1) | ES2199284T3 (da) |
IL (1) | IL117320A (da) |
NZ (1) | NZ303325A (da) |
PT (1) | PT813541E (da) |
SE (1) | SE9500778D0 (da) |
WO (1) | WO1996027608A1 (da) |
ZA (1) | ZA961679B (da) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9500778D0 (sv) * | 1995-03-03 | 1995-03-03 | Pharmacia Ab | Process for producing a protein |
SE9603068D0 (sv) | 1996-08-23 | 1996-08-23 | Pharmacia & Upjohn Ab | Process for purifying a protein |
SE9603304D0 (sv) | 1996-09-11 | 1996-09-11 | Pharmacia & Upjohn Ab | Process for purifying a compound |
SE9603303D0 (sv) | 1996-09-11 | 1996-09-11 | Pharmacia & Upjohn Ab | Process for purifying a protein |
DE19859703B4 (de) * | 1998-12-23 | 2009-10-29 | Macherey, Nagel Gmbh & Co. Handelsgesellschaft | Verfahren zur Aufreinigung von Nukleinsäuren sowie Anionenaustauscher zur Durchführung dieses Verfahrens |
US6410802B1 (en) | 1999-04-01 | 2002-06-25 | Esperion Therapeutics, Inc. | Methods for synthesizing ether compounds and intermediates therefor |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
EP2343317A1 (en) | 2000-11-10 | 2011-07-13 | F. Hoffmann-La Roche Ltd. | Apolipoprotein analogues |
JP2005504085A (ja) * | 2001-09-28 | 2005-02-10 | エスペリオン セラピューティクス,インコーポレイテッド | 薬剤の局所投与による再狭窄の予防および治療 |
US7470659B2 (en) | 2001-12-07 | 2008-12-30 | The Regents Of The University Of California | Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM) |
WO2003049685A2 (en) * | 2001-12-07 | 2003-06-19 | The Regents Of The University Of California | Treatment for age-related macular degeneration |
US20030229062A1 (en) * | 2001-12-07 | 2003-12-11 | The Regents Of The University Of California | Treatments for age-related macular degeneration (AMD) |
CN1668645A (zh) * | 2002-05-17 | 2005-09-14 | 埃斯佩里安医疗公司 | 治疗缺血再灌注的方法和组合物 |
US7335799B2 (en) | 2003-01-23 | 2008-02-26 | Esperion Therapeutics, Inc. | Hydroxyl compounds and compositions for cholesterol management and related uses |
TW200526778A (en) * | 2003-11-14 | 2005-08-16 | Sembiosys Genetics Inc | Methods for the production of apolipoproteins in transgenic plants |
US20050176623A1 (en) * | 2004-02-11 | 2005-08-11 | Neil Wagle | Non-invasive treatment of disease using amphipathic compounds |
JP2007531537A (ja) * | 2004-04-06 | 2007-11-08 | セダーズ−シナイ メディカル センター | アポリポタンパク質a−iおよびアポリポタンパク質a−imilanoをコードする組換えアデノ随伴ウイルスベクターによる血管疾患の予防および処置 |
KR100560102B1 (ko) * | 2004-06-25 | 2006-03-13 | 한국생명공학연구원 | 프로아포리포단백질 a-ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제 |
EP2269623A1 (en) | 2005-04-29 | 2011-01-05 | The Regents of The University of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
US20080227686A1 (en) * | 2006-06-16 | 2008-09-18 | Lipid Sciences, Inc. | Novel Peptides that Promote Lipid Efflux |
EP2041174A2 (en) * | 2006-06-16 | 2009-04-01 | Lipid Sciences, Inc. | Novel peptides that promote lipid efflux |
US20080206142A1 (en) * | 2006-06-16 | 2008-08-28 | Lipid Sciences, Inc. | Novel Peptides That Promote Lipid Efflux |
CN101489655A (zh) | 2006-07-14 | 2009-07-22 | 威斯康星旧生研究基金会 | 捕获病毒用吸附膜 |
CA2659655A1 (en) | 2006-08-08 | 2008-02-21 | Alan M. Fogelman | Salicylanilides enhance oral delivery of therapeutic peptides |
US20080138284A1 (en) * | 2006-09-26 | 2008-06-12 | Lipid Sciences, Inc. | Novel Peptides That Promote Lipid Efflux |
CN100586958C (zh) * | 2006-12-20 | 2010-02-03 | 上海莱士血液制品股份有限公司 | 高纯度载脂蛋白a-i的制备方法 |
US8013122B2 (en) * | 2006-12-20 | 2011-09-06 | Kieu Hoang | Method of purifying apolipoprotein A-1 |
US8557767B2 (en) | 2007-08-28 | 2013-10-15 | Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
DK2195331T3 (da) | 2007-08-28 | 2014-02-03 | Uab Research Foundation | Syntetiske polypeptider, der efterligner apolipoprotein e, og anvendelsesmetoder |
KR102344392B1 (ko) | 2008-11-10 | 2021-12-28 | 알닐람 파마슈티칼스 인코포레이티드 | 치료제 운반용 신규 지질 및 조성물 |
AU2010208035B2 (en) | 2009-01-29 | 2016-06-23 | Arbutus Biopharma Corporation | Improved lipid formulation for the delivery of nucleic acids |
NZ594995A (en) | 2009-03-12 | 2013-06-28 | Alnylam Pharmaceuticals Inc | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HUMAN KINESIN FAMILY MEMBER 11 (Eg5) AND VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) GENES |
NZ621981A (en) | 2009-05-05 | 2015-09-25 | Tekmira Pharmaceuticals Corp | Lipid compositions |
EA201791744A3 (ru) | 2009-06-10 | 2018-07-31 | Арбутус Биофарма Корпорэйшн | Улучшенная липидная композиция |
WO2011020023A2 (en) | 2009-08-14 | 2011-02-17 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
US9687550B2 (en) | 2009-12-07 | 2017-06-27 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
ES2749426T3 (es) | 2009-12-18 | 2020-03-20 | Univ British Columbia | Métodos y composiciones para administración de ácidos nucleicos |
WO2011139911A2 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
WO2011143362A1 (en) | 2010-05-11 | 2011-11-17 | Esperion Therapeutics, Inc. | Dimeric oxidation-resistant apolipoprotein a1 variants |
DK2575764T3 (da) | 2010-06-03 | 2017-08-07 | Alnylam Pharmaceuticals Inc | Biologisk nedbrydelige lipider til fremføring af aktive midler |
WO2012016184A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
WO2012016188A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
CN103370054A (zh) | 2010-11-09 | 2013-10-23 | 阿尔尼拉姆医药品有限公司 | 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法 |
EP2663548B1 (en) | 2011-01-11 | 2017-04-05 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
CN103443123B (zh) | 2011-02-07 | 2020-05-29 | 塞勒尼斯医疗控股公司 | 脂蛋白复合物及其制备和用途 |
EP2760477B1 (en) | 2011-09-27 | 2018-08-08 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
WO2013090319A2 (en) | 2011-12-12 | 2013-06-20 | Melior Pharmaceuticals I, Inc. | Treatment of type i and type ii diabetes |
WO2013180650A1 (en) | 2012-05-31 | 2013-12-05 | Agency For Science, Technology And Research | Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives |
US9610324B2 (en) | 2012-07-11 | 2017-04-04 | Esperion Therapeutics, Inc. | Apolipoprotein mixtures |
RU2016144908A (ru) | 2014-05-02 | 2018-06-05 | Серени Терапеутикс Холдинг Са | Маркеры hdl-терапии |
EP3189069A4 (en) | 2014-07-31 | 2018-03-07 | UAB Research Foundation | Apoe mimetic peptides and higher potency to clear plasma cholesterol |
CA2978204A1 (en) | 2015-03-13 | 2016-09-22 | Esperion Therapeutics, Inc. | Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
MA41793A (fr) | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
CN107033237B (zh) * | 2017-05-11 | 2021-07-20 | 深圳市卫光生物制品股份有限公司 | 一种人血浆载脂蛋白a-i的分离纯化方法 |
EP3986859A1 (en) | 2019-06-21 | 2022-04-27 | Esperion Therapeutics, Inc. | Methods of making bempedoic acid and compositions of the same |
WO2022035784A1 (en) * | 2020-08-10 | 2022-02-17 | Gel4Med, Inc. | Antifungal matrix formed from peptide hydrogels |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6196998A (ja) | 1984-10-16 | 1986-05-15 | Mitsubishi Chem Ind Ltd | ヒトアポリポプロテインa−i様蛋白の産生方法 |
AU587989B2 (en) * | 1984-10-16 | 1989-09-07 | Mitsubishi Chemical Corporation | DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins |
SE462100B (sv) * | 1985-08-08 | 1990-05-07 | Perstorp Ab | Komposition och dess anvaendning i ett tvaa- eller flerfassystem |
EP0262651A3 (en) * | 1986-09-30 | 1990-06-20 | Union Carbide Corporation | Isolation of enzyme values from solution |
GB8625435D0 (en) * | 1986-10-23 | 1986-11-26 | Erba Farmitalia | Human apolipoprotein ai |
US5128318A (en) * | 1987-05-20 | 1992-07-07 | The Rogosin Institute | Reconstituted HDL particles and uses thereof |
GB8712540D0 (en) * | 1987-05-28 | 1987-07-01 | Ucb Sa | Expression of human proapolipoprotein a-i |
JP2606228B2 (ja) * | 1987-09-18 | 1997-04-30 | 三菱化学株式会社 | ヒトプロアポリポプロテインa−i様蛋白の産生法 |
JP2561674B2 (ja) | 1987-10-06 | 1996-12-11 | 三菱化学株式会社 | 蛋白質の産生方法 |
CA1335077C (en) * | 1988-02-08 | 1995-04-04 | Henri Isliker | Process for the manufacture of apolipoproteins from human blood plasma or serum |
JPH01238534A (ja) * | 1988-03-17 | 1989-09-22 | Mitsui Toatsu Chem Inc | エンドトキシンの除去方法 |
EP0345155B1 (en) * | 1988-05-31 | 1994-08-10 | Mitsubishi Kasei Corporation | Process for producing natural human apolipoprotein e-like proteins |
DE3819463A1 (de) * | 1988-06-08 | 1989-12-14 | Behringwerke Ag | Expressionsvektoren zur herstellung unfusionierter proteine in mikroorganismen |
IT1229996B (it) * | 1989-04-20 | 1991-09-20 | Cesare Sirtori | Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine. |
WO1991006655A1 (en) * | 1989-10-31 | 1991-05-16 | Schering Corporation | E. coli secretory strains |
SE468881B (sv) * | 1991-01-09 | 1993-04-05 | Kabi Pharmacia Ab | Anvaendning av vissa foereningar foer framstaellning av laekemedel foer behandling av endotoxininducerade effekter samt saett att avlaegsna endotoxiner ur diverse loesningar |
WO1993000443A1 (en) * | 1991-06-26 | 1993-01-07 | Bio-Technology General Corp. | Purification of recombinant apolipoprotein e from bacteria |
SE9103701D0 (sv) * | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
US5733879A (en) * | 1992-06-12 | 1998-03-31 | N.V. Innogenetics, S.A. | Peptides and proteins, process for their preparation and their use as cholesterol acceptors |
SE9203753D0 (sv) * | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | Expression system for producing apolipoprotein ai-m |
JP3491917B2 (ja) * | 1993-02-05 | 2004-02-03 | メビオール株式会社 | 熱可逆性ハイドロゲル材料 |
US5643757A (en) * | 1994-03-21 | 1997-07-01 | American Cyanamid Company | High yield production of human apolipoprotein A1 in E. coli. |
JP3514514B2 (ja) * | 1994-06-14 | 2004-03-31 | 財団法人化学及血清療法研究所 | ヒト血漿からのアポリポ蛋白a−1の製造方法 |
SE9500724D0 (sv) * | 1994-06-23 | 1995-02-24 | Pharmacia Ab | Filtrering |
AU3151495A (en) * | 1994-08-01 | 1996-03-04 | James T Hsu | Lipoprotein cholesterol assays |
SE9500778D0 (sv) * | 1995-03-03 | 1995-03-03 | Pharmacia Ab | Process for producing a protein |
US5672685A (en) * | 1995-10-04 | 1997-09-30 | Duke University | Source of apolipoprotein E and method of isolating apolipoprotein E |
SE9603068D0 (sv) * | 1996-08-23 | 1996-08-23 | Pharmacia & Upjohn Ab | Process for purifying a protein |
-
1995
- 1995-03-03 SE SE9500778A patent/SE9500778D0/xx unknown
-
1996
- 1996-02-29 IL IL11732096A patent/IL117320A/en not_active IP Right Cessation
- 1996-03-01 ZA ZA961679A patent/ZA961679B/xx unknown
- 1996-03-01 US US08/875,125 patent/US5834596A/en not_active Expired - Lifetime
- 1996-03-01 DK DK96906136T patent/DK0813541T3/da active
- 1996-03-01 DE DE69628148T patent/DE69628148T2/de not_active Expired - Fee Related
- 1996-03-01 AU AU49607/96A patent/AU694623B2/en not_active Ceased
- 1996-03-01 EP EP96906136A patent/EP0813541B1/en not_active Expired - Lifetime
- 1996-03-01 WO PCT/SE1996/000271 patent/WO1996027608A1/en active IP Right Grant
- 1996-03-01 AT AT96906136T patent/ATE240348T1/de not_active IP Right Cessation
- 1996-03-01 NZ NZ303325A patent/NZ303325A/xx unknown
- 1996-03-01 ES ES96906136T patent/ES2199284T3/es not_active Expired - Lifetime
- 1996-03-01 PT PT96906136T patent/PT813541E/pt unknown
- 1996-03-01 CA CA002212125A patent/CA2212125A1/en not_active Abandoned
- 1996-03-01 JP JP8526799A patent/JPH11501046A/ja active Pending
-
1998
- 1998-08-05 US US09/129,720 patent/US5990081A/en not_active Expired - Lifetime
-
1999
- 1999-11-22 US US09/444,816 patent/US6506879B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US6506879B1 (en) | 2003-01-14 |
DE69628148T2 (de) | 2004-01-08 |
SE9500778D0 (sv) | 1995-03-03 |
US5990081A (en) | 1999-11-23 |
NZ303325A (en) | 1998-12-23 |
IL117320A0 (en) | 1996-06-18 |
PT813541E (pt) | 2003-09-30 |
JPH11501046A (ja) | 1999-01-26 |
AU4960796A (en) | 1996-09-23 |
US5834596A (en) | 1998-11-10 |
WO1996027608A1 (en) | 1996-09-12 |
ZA961679B (en) | 1996-10-07 |
EP0813541B1 (en) | 2003-05-14 |
AU694623B2 (en) | 1998-07-23 |
DE69628148D1 (de) | 2003-06-18 |
ATE240348T1 (de) | 2003-05-15 |
EP0813541A1 (en) | 1997-12-29 |
IL117320A (en) | 2001-06-14 |
ES2199284T3 (es) | 2004-02-16 |
CA2212125A1 (en) | 1996-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0813541T3 (da) | Fremgangsmåde til fremstilling af et protein | |
DK0658164T3 (da) | Fremgangsmåde til chromatografisk oprensning og adskillelse af nukleinsyreblandinger | |
SE9603068D0 (sv) | Process for purifying a protein | |
PT83205B (pt) | Metodo de purificacao e activacao de proteinas a partir de corpos de inclusao insoluveis | |
DE69637726D1 (de) | Gruppen zum einfangen von nukleinsäuren | |
DK0550509T3 (da) | Fremgangsmåde til fremstilling af rensede glycolipider ved membranseparationsmetoden | |
DE3576362D1 (de) | Verfahren zur reinigung einer physiologisch aktiven substanz, die durch rekombinante dna-technik hergestellt wurde. | |
DK0701623T3 (da) | Fremgangsmåde til fremstilling af N-acetyl-neuraminsyre | |
MY119738A (en) | Process for the purification of an alkanolamine | |
FR2632302B1 (fr) | Procede de recuperation d'acide citrique a partir d'une liqueur en contenant | |
DE69902639D1 (de) | Verbessertes verfahren zur herstellung von faktor viii | |
DE69112415D1 (de) | Verfahren zur herstellung von glukose und fruktose aus sukrose. | |
DE69902816D1 (de) | Synthese von heteropolysäuren | |
DE69738397D1 (de) | Verfahren zur aufreinigung von apolipoprotein-a oder apolipoprotein-e aus menschlichem plasma | |
DE69024392D1 (de) | Verfahren zur Reinigung von Aussenmembran-Protein von Haemophilus influenza | |
DK1001929T3 (da) | Fremgangsmåde til fremstilling af 3-cyano-2,4-dihalogen-5-flour-benzoesyrer | |
DE69101425T3 (de) | Methode zur Reinigung von rohem glycidyl (Meth)-Acrylat. | |
ATE361320T1 (de) | Monoklonaler antikörper gegen protein c inhibitor | |
SE0203551D0 (sv) | Prothrombin purification | |
EP0446850A3 (en) | Process for purifying recombinant human beta-interferon | |
AU8395698A (en) | Nucleic acid based immunotherapy of chronic hepatitis b infection | |
DK0466164T3 (da) | Fremgangsmåde til fremstilling af 2-chlor-1,7-dihydropurin-6-on og fremgangsmåde til rensning heraf | |
KR910015699A (ko) | 리포코틴의 정제방법 | |
FI916021A0 (fi) | Interferonin puhdistusmenetelmä | |
EP0387605A3 (de) | Verfahren zur stereoselektiven Herstellung von optisch aktiven S,S- oder R,R-beta-Aminoalkoholen |